Tuesday, December 27, 2016 1:40:40 PM
Would love to hear more about this opinion.
What is different about the batches, or to put a different way: what aspects of the nanoviricides are difficult to make consistently, in your opinion?
Is it the base polymer, nanomicelle size, distribution of particle size, production of ligands, self-assembling of nanomicelles at larger batches, coupling of the ligands to the nanomicelle, simply a lack of standardized testing/controls, or what do your inside sources tell you about the problem? Or is this just some random guess?
How are they able to replicate results from multiple labs if the nanoviricides are not reproducible to make? Are you saying every test that has been done has been sent from one batch?
What is different about the batches, or to put a different way: what aspects of the nanoviricides are difficult to make consistently, in your opinion?
Is it the base polymer, nanomicelle size, distribution of particle size, production of ligands, self-assembling of nanomicelles at larger batches, coupling of the ligands to the nanomicelle, simply a lack of standardized testing/controls, or what do your inside sources tell you about the problem? Or is this just some random guess?
How are they able to replicate results from multiple labs if the nanoviricides are not reproducible to make? Are you saying every test that has been done has been sent from one batch?
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
